Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy-Reference-Cited by-同舟云学术

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

Published:2016-08-25 Issue:8 Volume:128 Page:1112-1120
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Jurinovic Vindi¹²,Kridel Robert³,Staiger Annette M.⁴⁵,Szczepanowski Monika⁶,Horn Heike⁴⁵,Dreyling Martin H.¹,Rosenwald Andreas⁷,Ott German⁴,Klapper Wolfram⁶,Zelenetz Andrew D.⁸,Barr Paul M.⁹,Friedberg Jonathan W.⁹,Ansell Stephen¹⁰,Sehn Laurie H.³,Connors Joseph M.³,Gascoyne Randy D.³,Hiddemann Wolfgang¹¹¹,Unterhalt Michael¹,Weinstock David M.¹²,Weigert Oliver¹¹¹

Affiliation:

1. Medical Department III, University Hospital of the Ludwig Maximilians University Munich, Munich, Germany;

2. Institute for Medical Informatics, Biometry and Epidemiology, Ludwig Maximilians University Munich, Munich, Germany;

3. Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;

4. Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany;

5. Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Tübingen, Germany;

6. Hematopathology Section, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;

7. Institute of Pathology, University of Würzburg, and Comprehensive Cancer Center Mainfranken, Würzburg, Germany;

8. Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Medical College of Cornell University, New York, NY;

9. Wilmot Cancer Institute, University of Rochester, Rochester NY;

10. Division of Hematology, Mayo Clinic, Rochester, MN;

11. German Cancer Consortium and German Cancer Research Center, Heidelberg, Germany; and

12. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Abstract

Key Points The posttreatment end point progression of FL within 24 months (POD24) is strongly associated with OS. A pretreatment clinicogenetic risk model (m7-FLIPI) predicts POD24 and OS and identifies the smallest subgroup with highest unmet need.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/8/1112/1465676/1112.pdf

Reference27 articles.

1. How we manage follicular lymphoma.;Hiddemann;Leukemia,2014

2. Pathogenesis of follicular lymphoma.;Kridel;J Clin Invest,2012

3. Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis.;Mozessohn;Leuk Lymphoma,2014

4. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study.;Casulo;J Clin Oncol,2015

5. Event-free survival at 12 months (EFS12) from diagnosis is a robust endpoint for disease-related survival in patients with follicular lymphoma in the immunochemotherapy era [abstract].;Maurer;Blood,2014

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of the peripheral blood inflammatory indices and modified nomogram-revised risk index on survival of Extranodal Nasal-Type Natural Killer/T-Cell lymphoma;Cancer Biomarkers;2024-01-05

2. Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma;Leukemia & Lymphoma;2024-01-05

3. Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial;Annals of Oncology;2024-01

4. ARID1AMutations Protect Follicular Lymphoma from FAS-dependent Immune Surveillance by Reducing RUNX3/ETS1-Driven FAS-Expression;2023-12-13

5. R‐CHOP treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of JCOG0203;British Journal of Haematology;2023-11-23